The two end-points were evaluated both in the intention-to-treat (ITT) population and in the subset of patients with PD-L1-positive neoplasms, as defined by PD-L1 immunohistochemistry expression in ≥1% of cancer cells by a VENTANA PD-L1 SP142 assay. Here, CD274 is linked to neoplasm.